<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38548883</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5500</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Cancer gene therapy</Title><ISOAbbreviation>Cancer Gene Ther</ISOAbbreviation></Journal><ArticleTitle>Gastrointestinal infections and gastrointestinal haemorrhage are underestimated but serious adverse events in chimeric antigen receptor T-cell recipients: A real-world study.</ArticleTitle><Pagination><StartPage>710</StartPage><EndPage>720</EndPage><MedlinePgn>710-720</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41417-024-00752-0</ELocationID><Abstract><AbstractText>Chimeric antigen receptor T-cell (CAR-T) therapy has achieved durable response in patients with hematological malignancies, however, therapy-associated multisystem toxicities are commonly observed. Here, we systematically analyzed CAR-T-related gastrointestinal adverse events (GAEs) using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) between January 2017 and December 2021. Disproportionality analyses were performed using reporting odds ratios (ROR) and information component (IC). Among 105,087,611 reports in FAERS, 1518 CAR-T-related GAEs reports were identified. 23 GAEs (n = 281, 18.51%) were significantly overreported following CAR-T therapy compared with the full database, of which 11 GAEs (n = 156, 10.28%) were associated with gastrointestinal infections (GI), such as clostridium difficile colitis (n = 44 [2.90%], ROR = 5.55), enterovirus infection (n = 23 [1.52%], ROR = 20.02), and mucormycosis (n = 15 [0.99%], ROR = 3.09). Overall, the fatality rate of 11 GI-related AEs was 29.49%, especially mucormycosis causing substantial mortality with 60%. In addition, 4 of 23 overreported GAEs were related to haemorrhage and the mortality of gastrointestinal haemorrhage was 73.17%. Lastly, 29 death-related GAEs were identified. These findings could help clinicians early alert those rarely reported but lethal GAEs, thus reducing the risk of severe toxicities.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Song</LastName><ForeName>Zhiqiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Yuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China. liuna2015@sibs.ac.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China. chenjiedoctor@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jianmin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6572-1541</Identifier><AffiliationInfo><Affiliation>Department of Hematology, Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China. yangjianmin123@smmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>81770209</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country /></Grant><Grant><GrantID>82270202</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country /></Grant><Grant><GrantID>82300257</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country /></Grant><Grant><GrantID>82100162</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country /></Grant><Grant><GrantID>81970178</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cancer Gene Ther</MedlineTA><NlmUniqueID>9432230</NlmUniqueID><ISSNLinking>0929-1903</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006471" MajorTopicYN="Y">Gastrointestinal Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016219" MajorTopicYN="Y">Immunotherapy, Adoptive</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="Y">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076962" MajorTopicYN="N">Receptors, Chimeric Antigen</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>18</Day><Hour>4</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>29</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38548883</ArticleId><ArticleId IdType="doi">10.1038/s41417-024-00752-0</ArticleId><ArticleId IdType="pii">10.1038/s41417-024-00752-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39:1650–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33764809</ArticleId><ArticleId IdType="pmc">8274806</ArticleId><ArticleId IdType="doi">10.1200/JCO.20.02262</ArticleId></ArticleIdList></Reference><Reference><Citation>Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene Ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38:3119–28.</Citation><ArticleIdList><ArticleId IdType="pubmed">32401634</ArticleId><ArticleId IdType="pmc">7499611</ArticleId><ArticleId IdType="doi">10.1200/JCO.19.02104</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell Lymphoma. N. Engl J Med. 2019;380:45–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30501490</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1804980</ArticleId></ArticleIdList></Reference><Reference><Citation>Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia. N. Engl J Med. 2018;378:439–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">29385370</ArticleId><ArticleId IdType="pmc">5996391</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1709866</ArticleId></ArticleIdList></Reference><Reference><Citation>Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA−1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">30518502</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(18)30864-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">32888407</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)31366-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398:491–502.</Citation><ArticleIdList><ArticleId IdType="pubmed">34097852</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(21)01222-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018;132:777–81.</Citation><ArticleIdList><ArticleId IdType="pubmed">29914976</ArticleId><ArticleId IdType="pmc">6107879</ArticleId><ArticleId IdType="doi">10.1182/blood-2018-04-839217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeqi Nezhad M, Yazdanifar M, Abdollahpour-Alitappeh M, Sattari A, Seifalian A, Bagheri N. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology. Biotechnol Bioeng. 2021;118:3691–705.</Citation><ArticleIdList><ArticleId IdType="pubmed">34241908</ArticleId><ArticleId IdType="doi">10.1002/bit.27882</ArticleId></ArticleIdList></Reference><Reference><Citation>Tbakhi B, Reagan PM. Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). Ther Adv Hematol. 2022;13:20406207221080738.</Citation><ArticleIdList><ArticleId IdType="pubmed">35237395</ArticleId><ArticleId IdType="pmc">8882938</ArticleId><ArticleId IdType="doi">10.1177/20406207221080738</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey NV. Approval of brexucabtagene autoleucel for adults with relapsed and refractory acute lymphocytic leukemia. Blood. 2022;140:11−5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35507688</ArticleId><ArticleId IdType="doi">10.1182/blood.2021014892</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022;28:713–23.</Citation><ArticleIdList><ArticleId IdType="pubmed">35288695</ArticleId><ArticleId IdType="pmc">9434490</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01702-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019;94:S42–S49.</Citation><ArticleIdList><ArticleId IdType="pubmed">30784102</ArticleId><ArticleId IdType="doi">10.1002/ajh.25445</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20:359–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">37055515</ArticleId><ArticleId IdType="pmc">10100620</ArticleId><ArticleId IdType="doi">10.1038/s41571-023-00754-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Uribe-Herranz M, Beghi S, Ruella M, Parvathaneni K, Salaris S, Kostopoulos N, et al. Modulation of the gut microbiota engages antigen cross-presentation to enhance antitumor effects of CAR T cell immunotherapy. Mol Ther. 2023;31:686–700.</Citation><ArticleIdList><ArticleId IdType="pubmed">36641624</ArticleId><ArticleId IdType="pmc">10014349</ArticleId><ArticleId IdType="doi">10.1016/j.ymthe.2023.01.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Bureš J, Kohoutová D, Zavoral M. Gastrointestinal toxicity of systemic oncology immunotherapy. Klin Onkol. 2022;35:346–57.</Citation><ArticleIdList><ArticleId IdType="pubmed">36443091</ArticleId><ArticleId IdType="doi">10.48095/ccko2022346</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22:1403−15.</Citation><ArticleIdList><ArticleId IdType="pubmed">34516954</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(21)00375-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmood SS, Riedell PA, Feldman S, George G, Sansoterra SA, Althaus T, et al. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients. Eur Heart J. 2023;44:2029–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">36939851</ArticleId><ArticleId IdType="pmc">10256191</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehad117</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109−17.</Citation><ArticleIdList><ArticleId IdType="pubmed">10082069</ArticleId><ArticleId IdType="doi">10.2165/00002018-199920020-00002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang PS, Chen Z, Chan CL, Tai BC. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. Expert Opin Drug Saf. 2016;15:583–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">26996192</ArticleId><ArticleId IdType="doi">10.1517/14740338.2016.1167184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou Y, Ye X, Wu G, Cheng G, Du X, He J. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Expert Opin Drug Saf. 2014;13:853–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24918197</ArticleId><ArticleId IdType="doi">10.1517/14740338.2014.915938</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Z, Tu D, Tang G, Liu N, Tai Z, Yang J, et al. Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy. Haematologica. 2023;108:2067–79.</Citation><ArticleIdList><ArticleId IdType="pubmed">36794498</ArticleId><ArticleId IdType="pmc">10388276</ArticleId><ArticleId IdType="doi">10.3324/haematol.2022.281455</ArticleId></ArticleIdList></Reference><Reference><Citation>Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57–69.</Citation><ArticleIdList><ArticleId IdType="pubmed">21705438</ArticleId><ArticleId IdType="doi">10.1177/0962280211403604</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Müller-Tidow C, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32:34–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">33098993</ArticleId><ArticleId IdType="doi">10.1016/j.annonc.2020.10.478</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Qi K, Cheng H, Cao J, Shi M, Qiao J, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transpl. 2020;26:865–75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2019.11.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Ibañez AR, Upadhaya S, Partridge T, Shah M, Correa D, Campbell J. Landscape of cancer cell therapies: trends and real-world data. Nat Rev Drug Discov. 2022;21:631–2.</Citation><ArticleIdList><ArticleId IdType="pubmed">35650421</ArticleId><ArticleId IdType="doi">10.1038/d41573-022-00095-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai C, Tang D, Han Y, Shen E, Ahmed OA, Guo C, et al. A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. Aging (Albany NY). 2020;12:18741–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">32973124</ArticleId><ArticleId IdType="doi">10.18632/aging.104058</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Sbeih H, Tang T, Ali FS, Luo W, Neelapu SS, Westin JR, et al. Gastrointestinal adverse events observed after chimeric antigen receptor T-cell therapy. Am J Clin Oncol. 2019;42:789–96.</Citation><ArticleIdList><ArticleId IdType="pubmed">31478934</ArticleId><ArticleId IdType="doi">10.1097/COC.0000000000000596</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl J Med. 2017;377:2531–44.</Citation><ArticleIdList><ArticleId IdType="pubmed">29226797</ArticleId><ArticleId IdType="pmc">5882485</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1707447</ArticleId></ArticleIdList></Reference><Reference><Citation>Westin JR, Kersten MJ, Salles G, Abramson JS, Schuster SJ, Locke FL, et al. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA−1, and TRANSCEND trials. Am J Hematol. 2021;96:1295–312.</Citation><ArticleIdList><ArticleId IdType="pubmed">34310745</ArticleId><ArticleId IdType="pmc">9290945</ArticleId><ArticleId IdType="doi">10.1002/ajh.26301</ArticleId></ArticleIdList></Reference><Reference><Citation>Brudno JN, Natrakul D, Lam N, Dulau-Florea A, Yuan CM, Kochenderfer JN. Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. Leuk Lymphoma. 2022;63:1849–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">35389319</ArticleId><ArticleId IdType="doi">10.1080/10428194.2022.2056172</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54:1643–50.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-019-0487-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020;136:925–35.</Citation><ArticleIdList><ArticleId IdType="pubmed">32582924</ArticleId><ArticleId IdType="pmc">7441168</ArticleId><ArticleId IdType="doi">10.1182/blood.2019004000</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z, et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat Commun. 2022;13:5313.</Citation><ArticleIdList><ArticleId IdType="pubmed">36085303</ArticleId><ArticleId IdType="pmc">9461447</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-32960-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO Guideline. J Clin Oncol. 2021;39:3978–92.</Citation><ArticleIdList><ArticleId IdType="pubmed">34724386</ArticleId><ArticleId IdType="doi">10.1200/JCO.21.01992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, et al. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Oncologist. 2020;25:e321–e327.</Citation><ArticleIdList><ArticleId IdType="pubmed">32043764</ArticleId><ArticleId IdType="doi">10.1634/theoncologist.2019-0233</ArticleId></ArticleIdList></Reference><Reference><Citation>Philipson BI, O’Connor RS, May MJ, June CH, Albelda SM, Milone MC. 4−1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling. Sci Signal. 2020;13:eaay8248.</Citation><ArticleIdList><ArticleId IdType="pubmed">32234960</ArticleId><ArticleId IdType="pmc">7883633</ArticleId><ArticleId IdType="doi">10.1126/scisignal.aay8248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriakidis I, Mantadakis E, Stiakaki E, Groll AH, Tragiannidis A. Infectious complications of targeted therapies in children with leukemias and lymphomas. Cancers. 2022;14:5022.</Citation><ArticleIdList><ArticleId IdType="pubmed">36291806</ArticleId><ArticleId IdType="pmc">9599435</ArticleId><ArticleId IdType="doi">10.3390/cancers14205022</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusaroli M, Isgrò V, Cutroneo PM, Ferrajolo C, Cirillo V, Del Bufalo F, et al. Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA Adverse Event Reporting System (FAERS) Database. Drug Saf. 2022;45:891–908.</Citation><ArticleIdList><ArticleId IdType="pubmed">35829913</ArticleId><ArticleId IdType="pmc">9360149</ArticleId><ArticleId IdType="doi">10.1007/s40264-022-01194-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol. 2019;37:48–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">31187535</ArticleId><ArticleId IdType="doi">10.1002/hon.2595</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, et al. The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharm. 2022;13:950923.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.950923</ArticleId></ArticleIdList></Reference><Reference><Citation>Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295–306.</Citation><ArticleIdList><ArticleId IdType="pubmed">28924019</ArticleId><ArticleId IdType="pmc">5701525</ArticleId><ArticleId IdType="doi">10.1182/blood-2017-06-793141</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>